Search - tctmd.com

Displaying 781 - 800 of 896

Sort: Relevancy | Date

News Conference News EAS 2016

Good Fats, Bad Fats, and Sugar: A ‘Big Picture’ Approach Is Warranted With Diet Interventions for Cardiovascular Disease

Yael L. Maxwell

May 31, 2016

News Daily News

The Ups and Downs of Statin Adherence Around Acute MI Hospitalization

Todd Neale

May 25, 2016

News Daily News

Statins Tied to Lower Mortality, Amputation Risks in PAD

Michael O'Riordan

May 09, 2016

News Daily News

STICS: No Benefit to Perioperative Statin Therapy in Cardiac Surgery, but Acute Kidney Injury Risk Increased

Michael O'Riordan

May 05, 2016

News Features

Requiem for a Heavyweight: Big Brand Statin Era Comes to a Close as Crestor Heads Off-Patent

Michael O'Riordan

May 03, 2016

News Daily News

No More Niacin, Fibrate Combinations With Statins: FDA

Michael O'Riordan

April 19, 2016

News Daily News

虚拟组织学血管内超声研究显示，他汀类药物会改变冠状动脉斑块的构成

Michael O'Riordan

April 14, 2016

News Daily News

Un Estudio Histología-IVUS Revela que el Tratamiento con Estatinas Altera la Composición de las Placas Coronarias

Michael O'Riordan

April 14, 2016

News Daily News

Statin Therapy Alters Composition of Coronary Plaques, Virtual Histology-IVUS Study Shows

Michael O'Riordan

April 14, 2016

News Opinion Editor's Corner ACC 2016

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Shelley Wood

April 13, 2016

News Conference News ACC 2016

Hints of What’s to Come in New Coronary Revascularization AUC

Caitlin E. Cox

April 12, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Conference News ACC 2016

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

Michael O'Riordan

April 02, 2016

News Daily News

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

Michael O'Riordan

April 02, 2016

News Daily News

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

Michael O'Riordan

April 02, 2016

News Daily News

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

Michael O'Riordan

April 02, 2016

News Opinion Editor's Corner

ACC 2016: HOPE for Primary Prevention, TAVR in Moderate-Risk Patients, Deferred Stenting in STEMI, and More

Shelley Wood

March 28, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Daily News

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Michael O'Riordan

February 15, 2016

News Daily News

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Michael O'Riordan

February 15, 2016

Advertisement

Good Fats, Bad Fats, and Sugar: A ‘Big Picture’ Approach Is Warranted With Diet Interventions for Cardiovascular Disease

The Ups and Downs of Statin Adherence Around Acute MI Hospitalization

Statins Tied to Lower Mortality, Amputation Risks in PAD

STICS: No Benefit to Perioperative Statin Therapy in Cardiac Surgery, but Acute Kidney Injury Risk Increased

Requiem for a Heavyweight: Big Brand Statin Era Comes to a Close as Crestor Heads Off-Patent

No More Niacin, Fibrate Combinations With Statins: FDA

虚拟组织学血管内超声研究显示，他汀类药物会改变冠状动脉斑块的构成

Un Estudio Histología-IVUS Revela que el Tratamiento con Estatinas Altera la Composición de las Placas Coronarias

Statin Therapy Alters Composition of Coronary Plaques, Virtual Histology-IVUS Study Shows

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Hints of What’s to Come in New Coronary Revascularization AUC

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

HOPE-3: Reducing LDL Cholesterol Improves Outcomes in Intermediate-Risk Patients, but BP-Lowering Does Not

ACC 更新降低低密度脂蛋白胆固醇降低的建议，为依折麦布和 PCSK9 抑制剂留出了空间

ACC Updates LDL-Cholesterol Lowering Recommendations, Making Room for Ezetimibe and PCSK9 Inhibitors

ACC actualiza las recomendaciones para bajar el colesterol LBD, abriendo un espacio para el uso de Ezetimibe y de los inhibidores de PCSK9

ACC 2016: HOPE for Primary Prevention, TAVR in Moderate-Risk Patients, Deferred Stenting in STEMI, and More

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

研究认为有数据支持针对患者风险而非 LDL 胆固醇目标进行治疗

Según un Informe los Datos Avalan Tratar el Riesgo de los Pacientes No las Dianas de Colesterol LBD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content